Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Blakely CM, et al. Among authors: patil t. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028931 Free PMC article. Clinical Trial.
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL. Magnuson WJ, et al. Among authors: patil t. J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113019
First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. Iams WT, et al. Among authors: patil t. Clin Lung Cancer. 2018 Nov;19(6):531-543. doi: 10.1016/j.cllc.2018.08.011. Epub 2018 Aug 22. Clin Lung Cancer. 2018. PMID: 30197261 Free PMC article.
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR. Ng TL, et al. Among authors: patil t. J Thorac Oncol. 2019 Apr;14(4):596-605. doi: 10.1016/j.jtho.2018.12.001. Epub 2018 Dec 10. J Thorac Oncol. 2019. PMID: 30543838 Free article.
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Ng TL, et al. Among authors: patil t. Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11. Cancer. 2019. PMID: 30548240 Free article.
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Patil T, et al. Clin Lung Cancer. 2020 May;21(3):e191-e204. doi: 10.1016/j.cllc.2019.11.008. Epub 2019 Nov 21. Clin Lung Cancer. 2020. PMID: 31859066 Free PMC article.
303 results